Form 4: Twist Bioscience CFO Sells Shares for Tax Obligations

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 2,738 shares of common stock at $35.261 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (TWST), reported a transaction involving the company's common stock.
• On January 9, 2026, Mr. Laponis disposed of 2,738 shares of common stock.
• The shares were sold at a price of $35.261 per share.
• This sale was a 'sell to cover' transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The transaction was not a discretionary trade by Mr. Laponis.
• Following this transaction, Mr. Laponis beneficially owns 140,031 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary 'sell to cover' to satisfy tax obligations related to RSU vesting, which is a routine event and not indicative of management's discretionary view on the company's prospects.

Positives

• The underlying event for the share sale was the vesting of Restricted Stock Units, which represents compensation for the Chief Financial Officer.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This insider transaction is a routine event for executives receiving equity compensation and does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.

Key Dates

Recommendation

The reported transaction is a non-discretionary 'sell to cover' to satisfy tax withholding obligations upon the vesting of Restricted Stock Units. Such transactions are routine and do not typically reflect a change in the insider's view of the company's future prospects or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Twist Bioscience, TWST, Form 4, Insider Transaction, Adam Laponis, CFO, Stock Sale, Restricted Stock Units, Tax Withholding, Sell to Cover